Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs.
Bristol Myers Beats Quarterly Revenue Estimates On Strong Opdivo Sales
About the Author: ryounglao
Leave A Comment